Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
16
self-reported 11–50 band
Founded
2014
12 years
Legal entities
1
ABR
Office countries
1
1 address
Funding rounds
1
Series unknown · Feb 2017
Company type
Public Company
self-reported
Legal entity
1 brand → 1 confirmed entity
ACTINOGEN MEDICAL LIMITED
ABN14086778476
Legal entities
Show as table · Actinogen Medical: 1 registry entity
| ACTINOGEN MEDICAL LIMITED | ABN 14086778476 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Actinogen Medical (ASX:ACW) is an ASX-listed biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol.
There is a strong association between persistent stress and the production of excess cortisol that leads to changes in the brain affecting memory, cognitive function, behaviour and neuropsychological symptoms.
Actinogen’s lead compound, Xanamem, has been specifically designed to reduce production of intracellular cortisol - the stress hormone - through the inhibition of the 11β-HSD1 enzyme in the brain. The 11β-HSD1 enzyme is highly concentrated in the areas of the brain associated with cognitive impairment in early Alzheimer’s Disease (AD) and Depression, and other neurological and psychiatric diseases. Because of its ability to reach these areas of the brain and inhibit this enzyme, Xanamem is very different from other treatments for cognitive impairment.
Actinogen has studied 11β-HSD1 inhibition by Xanamem in more than 300 volunteers and patients, so far finding a statistically significant improvement in working memory and attention, compared with placebo, in healthy, older volunteers in two consecutive trials and clinically significant improvements in patients with biomarker-positive mild AD. Previously, high levels of target engagement in the brain with doses as low as 5 mg daily have been demonstrated in a human PET imaging study.
The Company is rapidly moving forward into its upcoming double-blind, randomized, placebo-controlled Phase 2 trials in cognitive impairment in Alzheimer’s Disease and Depression to further confirm and characterize Xanamem’s therapeutic potential. The XanaMIA Phase 2b AD trial comprises 330 patients with mild Alzheimer’s Disease and the XanaCIDD Phase 2a trial will total 160 patients with depression.
Specialties
All 4 specialties
- Biotechnology
- Clinical Development
- Pharmaceuticals
- Clinical Research
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | AU |
All codes: AU
Addresses
- AUSuite 901, Level 9; 109 Pitt Street; Sydney, NSW 2000Primary
Grid intelligence Members
Funding
Last round · 1 February 2017Amount not recordedSeries unknown
Rounds1
Round typeSeries unknown · venture round
Amount (USD)not recorded
Stage ranknot recorded
Investors named0
Since last round8 yr 11 mo
Funding
Show as table · 1 funding round
| Rounds | 1 |
|---|---|
| Axis | 2014 to 2026 |
| Series unknown · 1 Feb 2017 | not disclosed |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Counts only. No names are stored here, and none are served.
FAQ
Which legal entity operates under Actinogen Medical?
One New South Wales entity on the ABR. ACTINOGEN MEDICAL LIMITED (ABN 14 086 778 476), high confidence.
How many people work at Actinogen Medical?
The record holds 16 counted staff profiles at January 2026, inside the self-reported 11–50 band.
Where does Actinogen Medical have offices?
One address on record, Australia only. Primary: Suite 901, Level 9, 109 Pitt Street, Sydney, NSW 2000.
Has Actinogen Medical raised funding?
One round. Latest 1 February 2017: Series unknown, no amount recorded.
What does Actinogen Medical list as its specialties?
Four tags on the brand's own list, among them biotechnology, pharmaceuticals and clinical research.
Which companies are listed alongside Actinogen Medical?
8 profiles list Actinogen Medical as a peer — 76th percentile in Biotechnology. It lists ten peers of its own. Myopharm Limited and Touch Biotechnology list it back.